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Abstract 
This study was designed to experimentally evaluate the optimal X-ray energy for increasing the radiation 
energy absorbed in tumours loaded with iodinated compounds, using the photoelectric effect. SQ20B 
human cells were irradiated with synchrotron monochromatic beam tuned at 32.8, 33.5, 50 and 70 keV. 
Two cell treatments were compared to the control: cells suspended in 10 mg ml1 of iodine radiological 
contrast agent or cells pre-exposed with 10 mM of iodo-desoxyuridine (IUdR) for 48 h. Our radiobiological 
end point was clonogenic cell survival. Cells irradiated with both iodine compounds exhibited a radiation 
sensitisation enhancement. Moreover, it was energy dependent, with a maximum at 50 keV. At this energy, 
the sensitisation calculated at 10% survival was equal to 2.03 for cells suspended in iodinated contrast 
agent and 2.60 for IUdR. Cells pretreated with IUdR had higher sensitisation factors over the energy range 
than for those suspended in iodine contrast agent. Also, their survival curves presented no shoulder, 
suggesting complex lethal damages from Auger electrons. Our results confirm the existence of the 50 
keV energy optimum for a binary therapeutic irradiation based on the presence of stable iodine in tumours 
and an external irradiation. Monochromatic synchrotron radiotherapy concept is hence proposed for 
increasing the differential effect between healthy and cancerous tissue irradiation. 
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This study was designed to experimentally evaluate the optimal X-ray energy for increasing the radiation energy absorbed in tumours
loaded with iodinated compounds, using the photoelectric effect. SQ20B human cells were irradiated with synchrotron
monochromatic beam tuned at 32.8, 33.5, 50 and 70 keV. Two cell treatments were compared to the control: cells suspended in
10 mg ml1 of iodine radiological contrast agent or cells pre-exposed with 10mM of iodo-desoxyuridine (IUdR) for 48 h. Our
radiobiological end point was clonogenic cell survival. Cells irradiated with both iodine compounds exhibited a radiation sensitisation
enhancement. Moreover, it was energy dependent, with a maximum at 50 keV. At this energy, the sensitisation calculated at 10%
survival was equal to 2.03 for cells suspended in iodinated contrast agent and 2.60 for IUdR. Cells pretreated with IUdR had higher
sensitisation factors over the energy range than for those suspended in iodine contrast agent. Also, their survival curves presented no
shoulder, suggesting complex lethal damages from Auger electrons. Our results confirm the existence of the 50 keV energy optimum
for a binary therapeutic irradiation based on the presence of stable iodine in tumours and an external irradiation. Monochromatic
synchrotron radiotherapy concept is hence proposed for increasing the differential effect between healthy and cancerous tissue
irradiation.
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Megavoltage radiation beams are nowadays widely used for
anticancer radiotherapy. High-energy linear accelerators allow
highly penetrating radiation to treat targeted volumes with a better
sparing of superficial healthy tissues. Moreover, in this range of
energies (1–25 MeV), photons beams mainly interact with living
matter by Compton scattering processes, almost independent of
the composition of the traversed material. Thus, a highly
homogeneous dose distribution is achievable in the human body
and predicted accurately by Monte-Carlo based three-dimensional
treatment planning systems.
Lower energy beams are preferred for medical imaging. Kilo-
voltage X-ray beams are used for the production of radiological
images and the predominant physical process in high-density
materials is the photoelectric effect, which is strongly Z-dependent.
Hence, attenuation in bone is far higher than for soft tissues, and
the radiological contrast rely on photoelectric processes. The
spectra of these X-ray tube beams vary between 10 and 250 keV.
Healthy tissue tolerance remains the major limiting factor of
anticancer radiotherapy and techniques are investigated to
enhance the local control of tumours by increasing the absorbed
X-ray dose, while preserving more efficiently the healthy
surrounding tissues.
Dual modalities like Boron Neutron Capture Therapy (BNCT)
propose enhancing the neutron capture reaction cross-sections in
a stable boron-loaded tumour (Barth et al, 1990). Toxicity of the
irradiation is increased in the tumour by the production of high
linear energy transfer alpha and lithium ion particles. The neutron
dose enhancement is highly correlated to the boron concentration
present inside the tumour at the time of the irradiation. The most
limiting factor remains the boron concentrations achievable
(Soloway et al, 1994; Coderre et al, 1998) and their in vivo
measurement (Verbakel and Stecher-Rasmussen, 2001). Never-
theless, clinical trials are underway for patients with high-grade
brain gliomas, which remains a hardly curable tumour type.
For photon beams, a bimodal approach known as ‘Photon
Activation Therapy’ has been proposed in the early 1970s (Tisljar-
Lentulis et al, 1973; Tisljar-Lentulis and Feinendegen, 1977). High-
Z heteroatoms in DNA could be used for increasing kilovoltage X-
ray killing efficiency, by generating photoelectric events. Ionised
heavy atoms then reorganise and emit low-energy Auger electrons
cascades, able to damage DNA because of their nuclear localisa-
tion. In a less specific way, Norman et al developed another
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approach: the use of a conventional kilovoltage scanner to treat
iodine-loaded tumours (Iwamoto et al, 1990; Rose et al, 1999). By
increasing the tumour density and focussing a kilovoltage beam on
it, interaction cross-sections are improved in the tumour only, due
to the photoelectric effect, and the dose distribution is concen-
trated inside the tumour (Solberg et al, 1992a, 1995; Mesa et al,
1999). Moreover, tumour imaging is achievable during treatment
with this scanner. The lack of such a modality is actually a
weakness of current megavoltage radiotherapy treatments. The
physical properties of high-energy beams allow good dose
distribution characteristics but do not allow good imaging yet.
What would be the optimal X-ray energy, if any, for irradiating
tumours loaded with high-Z elements? Considering a heavy
element introduced to living matter as isolated atoms, irradiation
with an energy just above the K-edge appears conceptually as the
best option to enhance energy deposition by the contribution of
Auger electrons events. This concept has been tested with iodine
and other heavy atoms, irradiated with either monochromatic
radioactive sources (Nath et al, 1990), or synchrotron X-rays
(Laster et al, 1993; Hieda et al, 1996). Laster et al obtained
convincing results with iodine incorporated into DNA as 5-iodo-
20-deoxyuridine (IUdR). Others, as Solberg et al (1992a) and
Karnas et al (1999) suggested, by calculation, that the optimal
energy should be far above the iodine K-edge and around 50 keV
because it corresponds to the energy level where the difference
between the mass energy absorption coefficients of water and
iodine is the largest. Therefore, two different concepts were to be
considered: the first one based on the occurrence of particular
events; the second one taking into account the difference in
absorption capacity of the living matter with and without the
presence of a certain concentration of iodine, whatever the
structure imbedding it.
As pointed out by Karnas et al (1999) and Solberg et al (1992b),
monochromatic X-rays produced by a synchrotron should be the
best tool for verifying these hypotheses. Powerful third generation
synchrotrons are now available to deliver broad X-ray beams
(10– 100 keV), brilliant enough for using monochromators and
able to precisely select the desired X-rays energy. At the European
Synchrotron Radiation Facility (ESRF, Grenoble, France), the ID17
beamline is dedicated to medical applications of synchrotron
radiation (Thomlinson et al, 2000) and is designed for human in
vivo experiments (Elleaume et al, 1999, 2000a).
In this paper we report the experimental demonstration of the
existence of an optimal value of the enhancement ratio produced
by the presence of iodine compounds. We studied its variation
along the energy spectrum from 30 to 70 keV in two different
experimental settings: extracellular iodine from contrast agent and
iodine incorporated into DNA as IUdR.
METHODS AND MATERIALS
Chemicals
5-iodo-20-deoxyuridine was provided by Lausanne University
Hospital Pharmacy (Switzerland) as lyophilised powder. Iodinated
radiographic contrast agent used for extracellular iodine was
Iomerons (Bracco, Milano, Italy), which is a nonionic, monomeric
iodine compound containing 350 mg of iodine per ml of solution.
Cell line
The SQ20B cell line was derived from a human head and neck
squamous carcinoma (Weichselbaum et al, 1986) and was obtained
from William K Dahlberg (Dr JB Little Laboratory, Harvard School
of Public Health). This cell line is commonly used for radio-
biological research, and has been handled as previously described
(Corde et al, 2002). The SQ20B doubling time is 21 h.
Cell culture technique, colony-forming assay
Cells were seeded and grown as monolayer in plastic tissue culture
disposable flasks (Falcon) with 0.4 ml cm2 Dulbecco’s modified
Eagle’s minimum medium (Gibco-BRL), added with 10% foetal calf
serum (Gibco-BRL), penicillin and streptomycin (Gibco-BRL).
Cells were grown at 371C in a humidified atmosphere of 5% CO2 in
air.
When IUdR was used, 48 h before irradiation, cell cultures were
incubated with 10 mM IUdR (1.3 mg iodine l1), diluted in fresh
medium. Before irradiation, cells were trypsinised and experiments
were carried out with the cell suspension in 2 ml sterile cryotubes
(Merck Eurolab) with or without Iomerons (10 g iodine l1) added
to the culture medium, according to the experimental protocol.
Three independent experiments have been carried out and
averaged. After each irradiation, triplicate low-density subcultures
of the cells were established in +100 mm Petri dishes for colony-
forming assay. Colonies were fixed and stained with violet crystal
oxalate (Merck Eurolab) after 15 days of cell growing.
Irradiation procedure
Irradiation was carried out at room temperature in aerobic
conditions at the ESRF medical beamline (ID17) (Elleaume et al,
1999). Cells were irradiated as suspension in horizontal con-
tinuously rotating cryotubes (2 ml, 10 mm in diameter), vertically
translated up-and-down through a 500-mm-thick X-ray beam
providing a dose rate calculated in water of about 0.5 Gy s1. Dose
calibrations were performed using a cylindrical ion chamber (PTW
31002) coupled with a Unidoss electrometer. They were cross-
checked with a high-purity Germanium detector (Eurisys Mesur-
ess, Lingolsheim, France). Real-time control of delivered doses
was provided by a 10 cm long nitrogen filled ion chamber,
continuously present in the beam.
Energies were tuned with an accuracy of 7100 eV. The dose rate
was equal for all the tested energies, which were 32.8, 33.5, 50 and
70 keV. We point out that the K-edge of iodine is 33.169 keV. This
setting was obtained with an Si(111) fixed-exit monochromator,
designed for computed tomography with synchrotron radiation as
previously described (Suortti et al, 2000; Corde et al, 2002). The
ESRF storage ring was operating in its ‘uniform mode’, providing a
storage ring current decreasing from 200 to 170 mA with a lifetime
of 60 h.
Data analysis
Colonies with more than 50 cells were counted using digital images
of Petri dishes containing fixed and stained clones, associated with
a computer assisted image analysis system (Samba Technologies,
Meylan, France) as previously described (Biston et al, 2003), which
allows to avoid subjective bias in the procedure.
Experimental data were fitted with the linear quadratic model
(LQ):
S ¼ expðaD  bD2Þ
where S is the survival probability, D the radiation dose (Gy), a
and b are the fit parameters (Gy1 and Gy2 respectively).
Enhancement ratio
We used two different ratios to measure the dose modifications
produced by the iodine.
The sensitisation enhancement ratio at ‘S%’ of survival, SERs%
was calculated from the experimental cell survival curves and
defined as the ratio of doses (sensitised to control) that yielded a
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given cell survival level of S%:
SERs%¼
DcontrolS
D
exp
S
The theoretical expected dose enhancement ratio, DER, was
calculated from the variation of the mass energy-absorption
coefficient of the target due to the presence of iodine:
DER ¼
men
r
 waterþiodine
E
men
r
 water
E
¼
wI
men
r
 iodine
E
þð1  wIÞ menr
 water
E
men
r
 water
E
where
men
r
 
E
is the mass energy absorption coefficient for the considered
compound irradiated with monochromatic X-rays beam (energy:
E) and wI is the fraction by weight of iodine in the mixture.
RESULTS
Energy dependence of the DER for different iodine
concentrations in water
DER variation with photon energy has been represented in Figure 1
from Hubble physical data references (Hubbell and Seltzer, 1997).
This variation is a bell-shaped curve having its maximum around
50 keV. The maximum DER is strikingly increased when the iodine
concentration in water is rising up to 100%, reaching about 160.
The range of energies yielding such a sharp variation is rather
narrow from the K-edge of iodine (33 keV) up to about 80 keV.
Experimental energy dependence of the SER for cells
irradiated with 10 mg ml1 of extracellular iodine in
medium
Survival curves of SQ20B cells are displayed in Figures 2A– C,
showing the modifications of the dose –effect relationship for
synchrotron radiation of different energies with or without
10 mg ml1 of iodine introduced as Iomerons. These experimental
results have been obtained with a constant dose rate whatever the
energy level. It appears that the radiosensitisation is energy
dependent.
The comparison of experimental SER10% with the calculated
DER, according to the energy, is shown in Figure 3. The variation
in the behaviour of both parameters with energy is similar with the
same apparent maximum at 50 keV but experimental results are
constantly lower than predicted. The experimental SER10%
increases slightly when the energy goes through the iodine K-edge
(from 1.05 to 1.23), but reaches its maximum for 50 keV (1.95) and
decreases again for 70 keV as the theory predicts.
Experimental energy dependence of the SER for cells
irradiated with 10 lM of iodine incorporated in DNA as
IUdR
The same experiment was performed with iodine incorporated into
the cell nucleus as iodinated nucleotide by exposure to 10 mM IUdR
during 48 h followed by irradiation at different energy levels. Once
again, we observed a cell sensitivity energy dependence, for the
same dose rate of monochromatic irradiation, as shown in Figures
4A– C. Similarly, 50 keV is the energy yielding the maximum
cytotoxic effect. The experimental SER10% obtained is 2.6 for
1
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Figure 1 Energy dependence of the theoretical dose-enhancement ratio
for several iodine aqueous mixtures (from bottom to top, the mass
proportion of iodine in water, wI is ranging from 0.01 to 1).
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Figure 2 Survival curves of SQ20B cells irradiated with (open symbols) or without (closed symbols) 10 mg ml1 iodine incorporated as contrast agent in
medium, for the energies: (A) around iodine K-edge: 32.8 keV (triangles) and 33.5 keV (reversed triangles); (B) 50 keV (squares); (C) 70 keV (circles). Each
survival curve fit is derived from the dose and surviving fraction data (triplicate experiments).
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50 keV, and the difference below vs above the K-edge of the iodine
is fairly reduced, the values are, respectively, 1.25 and 1.64.
Comparison of the effects of both iodine compounds
Figure 5 compares the SER10% obtained with SQ20B cells irradiated
at different energies with either 10 mg ml1 extracellular iodine or
intracellular iodine incorporated into the nucleus as IUdR. For the
same survival level, namely 10%, the intracellular situation of
iodine proved to be more efficient than the extracellular case
except for the highest energy of 70 keV.
Interestingly, the comparison of survival curves from Figure 2
and 4 shows a more deeply altered shape for intracellular iodine
than for the extracellular iodine. The initial shoulder is strongly
reduced giving a high-TEL-radiation-like shape for intracellular
iodine. As an illustration, Figure 6 shows the variation of the
SERs%, according to the survival level, measured at 50 keV. A
striking difference is observed between both iodine situations. For
intracellular iodine, the sensitisation enhancement ratio increases
from 2.6 for a survival rate of 10% up to almost 10 for 90%
survival. For the extracellular iodine, the sensitisation enhance-
ment ratio is almost constant around 2.
DISCUSSION
The sensitivity of SQ20B cells to kilovoltage X-ray beams is
enhanced in the presence of the iodine compounds, whatever its
subcellular localisation. This enhancement depends upon the
choice of the X-ray energy beam, as predicted by the theoretical
DER curves (Figure 1).
Iodine contrast agent as radiation sensitiser
When extracellular iodinated contrast agent was used, experi-
mental values of the enhancement ratio, estimated at 10% of the
surviving fraction from the linear-quadratic interpolation of the
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Figure 3 Comparison of the energy dependence of the calculated dose-
enhancement factor (DER) with the measured one at 10% survival level
(SER10%), for 10 mg ml
1 of extracellular iodine.
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Figure 4 Survival curves of SQ20B cells irradiated with (open symbols) or without (closed symbols) a 48-h pre-exposure to 10 mM IUdR, for the energies:
(A) around iodine K-edge: 32.8 keV (triangle) and 33.5 keV (reversed triangle); (B) 50 keV (square); (c) 70 keV (circle). Each survival curve fit is derived from
the dose and surviving fraction data (triplicate experiments).
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Figure 5 Comparison of the energy dependence of the sensitization
enhancement ratio (SER10%) for cells pretreated with 10 mM IUdR for 48 h
or irradiated with 10 mg ml1 of iodine incorporated in their medium as
contrast agent.
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survival curves, was systematically inferior to the DER by a factor
varying between 23% (50 keV) to 40% (33.5 keV).
Such differences between the calculated and the experimental
enhancement ratio could be explained by different factors:
(i) Since not all energy deposited results in cell killing, the
theoretical dose enhancement ratio will always overestimate in
vitro or in vivo measurements.
(ii) The experimental working conditions are arbitrary (choice of
the cell line, geometry of the setup, cell density during
irradiation).
(iii) Calculation of the theoretical factor does not take into account
the experimental geometry: a physical autoabsorption of the
photoelectrons by the medium itself and as a consequence less
radiation dose seen by the cells in suspension in their medium
could be taken into consideration by finer simulations.
(iv) Finally, the survival rate level chosen for the comparison is of
prime importance as suggested in Figure 6.
Nevertheless, the shape of both the enhancement ratio variations
are consistent, with an experimental maximum at 50 keV and a
minimum just below the iodine K-absorption edge (Figure 3).
Moreover, this enhanced radiosensitivity is concentration depen-
dent, as published elsewhere (Estève et al, 2002).
We interpret the lethal effect enhancement observed as closely
linked to photoelectric interaction on the high-Z atoms present in
the vicinity of the SQ20B cells (Callisen et al, 1979). As studied by
Matsudaira et al (1980), the use of more energetic radiation, such
as g for instance, would not imply similar results. With these
energies comparable with the ones used in radiotherapy, Compton
scattering is the major physical interaction and does not vary
sufficiently with the matter composition for giving probing
enhancement factors (Robar et al, 2002). Matsudaira et al (1980)
demonstrated with a 200 kVp polychromatic (p) X-rays tube that
5% of iodine in the cell growing medium modified cellular
response to the irradiation, but no effect was shown with
irradiation from 60Co.
We extrapolated their survival curve data and estimated that the
SER10% factor was equal to 2.24 for 50 mg ml
1 of iodine and
200 kVp irradiation. Dawson et al (1987) have found similar results
with an SER10% estimated from their data to be around 1.8 for
20 mg ml1 of iodine and 250 kVp irradiation. Interpolation of their
data to 10 mg ml1 of iodine would have led to a sensitisation
enhancement ratio of 1.3. This factor has been increased to 2.25 by
using a lower energy X-ray beam of 140 kVp (Iwamoto et al, 1987;
Solberg et al, 1992a). Nevertheless, this last value has not been
calculated from survival curves data, but from micronuclei
formation in cells postirradiation.
These experimental demonstrations of the radiotoxicity en-
hancement of low- and medium-energy X-rays due to the presence
of iodinated contrast agents had some consequences in radi-
ological diagnosis, mainly because of the fear of mutagenic effects
postexamination (Adams et al, 1977; Norman et al, 1978, 2001).
Nevertheless, the X-ray doses implied in such examinations are not
comparable with the therapeutic ones.
Based on these results, a brand new radiotherapy technique
called CTRx for computed tomography radiotherapy was put
forward by Norman and collaborators. They propose using a
classical scanner (voltage 140 kVp) slightly modified for allowing
field collimation, adjustable to tumour sizes. The aim of the
technique is to obtain sharp isodoses around the tumour, using
both the photoelectric effect on the high-Z element present in the
tumour and the circular irradiation ballistic (Mesa et al, 1999).
Phase I clinical trial was published for treatment of patients with
metastatic brain tumours, loaded with iodinated contrast agents,
and demonstrated the feasibility of this technique (Rose et al,
1999). The dose-enhancement effect is hence theoretically opti-
mised with 140 kVp X-rays beams when compared with 10 MV,
and, interestingly enough even in cases of stereotactic irradiation.
However, polychromatic conventional X-ray tubes do not lead to
an optimum energy deposition inside the iodine-loaded tumour
(X-ray spectrum hardening with depth). Synchrotron X-rays beam
should allow the choice of the optimal X-ray energy for energy
absorption enhancement inside the iodinated tumour compared
with healthy nonloaded tissues (Solberg et al, 1992b).
Our results show that this optimal energy does exist and
according to our calculations, its value is around 50 keV. For this
particular energy, the SER10% measured on our cell line is 2.03 for
10 mg ml1 of iodine incorporated as contrast agent in the
medium. This sensitisation value appears to have the same order
of magnitude for monochromatic beam in comparison with the
results quoted above with polychromatic beams. Nevertheless,
such comparisons have to be made carefully and are always
difficult when different cell lines are considered. It should be
stressed that SQ20B cell line is particularly radioresistant and
nonapoptotic (Brachman et al, 1993).
Another advantage of the synchrotron radiation beam, for this
bimodal approach, is the imaging scanner tool, which was
developed on the ESRF ID17 medical beamline (Elleaume et al,
2000b, 2002). It allows the in vivo measurement of absolute
tumoral iodine concentrations (Le Duc et al, 2000), which is an
essential parameter for planning the doses to be delivered. This
advantage is not available with other bimodal approaches: neither
with conventional scanners due to beam hardening nor for BNCT
as previously mentioned. This could be a valid argument for
considering this technique for clinical trial evaluation.
Iodine incorporated into DNA as IUdR: subcellular and
energetic optimisations
5-iodo-20-deoxyuridine was used in this study to optimise the
subcellular localisation of iodine compounds. 5-iodo-20-deoxyur-
idine does not remain extracellular as contrast agents, but directly
substitutes DNA thymidine base, and is hence incorporated inside
the DNA morphology during its replication in cycling cells
(Pomplun and Terrissol 1994). This compound is known to
sensitise mammalian cells to damage induced by ionizing
radiation, both in vitro and in vivo. The underlying sensitisation
mechanism is not yet fully understood but could rely on alteration
of the DNA structure (Iliakis and Kurtzman, 1989) or a decrease in
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Figure 6 Comparison of the survival level dependence for the
calculation of the experimental factor SERS% for cells irradiated at 50 keV
either with a 48 h pre-exposure to 10 mM IUdR (closed symbols) or with
10 mg ml1 iodine incorporated in the medium via a contrast agent (open
symbols).
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cell reparability (Wang and Iliakis, 1992; Wang et al, 1994). As this
compound requires a cellular proliferation activity, it has the
property to target tumours having high proliferation rates.
The photonic activation of stable iodine atoms, incorporated in
DNA with IUdR, was first proposed by Fairchild et al (1982). They
calculated a sensitisation factor comprised between 1.5 and 3
depending on the percentage of thymidine replacement. This
technique avoids the drawbacks of IUdR labelled with Auger
emitters radioisotopes, which are also toxic for healthy fast-
growing tissues such as the bone marrow.
Whereas clinical use of IUdR in association with megavoltage X-
rays beams brought to reserved results (Epstein et al, 1992),
photon activation therapy proposed by Fairchild and Bond (1984)
was based not only on IUdRs use but also on the idea of an
energetic optimisation of the X-ray beam too. Photoelectric
absorption discontinuities of the isolated heavy atoms lead to
the conclusion that the energy just above the K-absorption edge of
iodine was the optimal one. Laster et al (1993) demonstrated, for
this particular energy, that the dose necessary to decrease the
surviving V79 cells fraction to 10% was three times less for cells
pre-exposed to 6 mM IUdR for 14 h (16% substitution) than for the
untreated cells. This value decreased to 1.4-fold less when
synchrotron X-rays energy was just below the iodine K-edge.
These are the most satisfying results yet, among a series of similar
works, which had common objectives but used different
experimental methods. A sensitisation ratio equal to 1.8 has
been observed by Shinohara et al (1996) with 20% thymidine
bases substituted by iodine from IUdR and a g-irradiation from
60Co. Another study with 137Cs irradiation and similar iodine
content gave comparable results (Fairchild et al, 1985). This factor
was found to be equal to 1.5 by Nath et al (1987) with 250 kVp
X-rays.
The choice of the optimal X-ray energy for irradiating IUdR
pretreated cells is investigated in the present work, similarly to
Karnas et al (1999, 2001a). Theoretical calculation of the DER
relative to the presence of 10 mM of IUdR during the irradiation in
water would be negligible, very close to 1, except if this factor is
calculated at the microscopic level, as suggested by Karnas et al In
that case, a DER comprised between 2 and 3 for 50 keV irradiation
is expected for a 10–30% thymidine base replacement by iodine.
Other authors have reported comparable measured DNA iodine
contents for exposure of exponentially growing cells. Hence, for a
10 mM IUdR during a double cell cycling time (48 h), a thymidine
substitution ranging between 10 and 20% is expected (Laster et al,
1993).
Consequently, our experimental results are in good agreement
with the calculations made by Karnas et al (1999). Due to the lack
of available synchrotron sources, adjustable monochromatic
beams were not used to validate their calculation, but CHO cells
exposed to 10 mM IUdR for 3 days and irradiated with medium
energy X-ray tube (100 kVp) exhibited SER1% of 1.8 vs 1.4 for low-
energy spectrum (30 kVp). By filtrating the 100 kVp beam with
tungsten, SER1% reached a value of 2.7, corresponding to a
thymidine substitution by iodine of 18%.
With a monochromatic beam, SER10% for SQ20B cells pre-
exposed for 48 h to 10 mM IUdR was found to be equal to 2.62 at
50 keV. This energy corresponds to the experimental maximum of
radiosensitisation. Interestingly, around the K-edge of iodine,
SER10% slightly increases by crossing the edge (from 1.25 to 1.64)
but our enhancement ratios remain low in comparison with some
other published data (Laster et al, 1993). Moreover, energies
around the K-edge are experimentally found not to be optimal for
increasing the differential effect between treated and untreated
cells.
Owing to the energy dependence of the sensitisation found for
cells pretreated with IUdR, it is more likely due to the photoelectric
effect than to an intrinsic sensitisation action of IUdR, for which
an energy dependence could hardly be expected.
Comparison of the effects of both iodine compounds
Pre-exposure of cells to 10 mM IUdR for 48 h leads to greater
sensitisation enhancement ratios than the presence of 10 mg ml1
of iodine as contrast agent in the medium (Figure 5). 5-iodo-20-
deoxyuridine is 30% more efficient at 33.5 and 50 keV, 20% more
at 32.8 keV and sensitisation ratios appear to be the same at
70 keV. Above the K-edge of iodine, photoelectrons from the K
shell are extracted with a kinetic energy of 300, 18.8 and 36.8 keV
for 33.5, 50 and 70 keV excitation energies, respectively. Reported
to the nucleus and cellular dimensions, the range of photoelectrons
emitted by iodine atoms placed inside the DNA is then less critical
for the highest energies studied. The biological efficiency of photon
activated IUdR with regard to the extracellular iodine could be
explained by damages produced directly inside the DNA by Auger
electrons. These low-energy electron cascades are known to be
biologically efficient and extremely toxic, but only if generated in
the nucleus or preferably in the DNA (Commerford et al, 1980;
Faraggi et al, 1994; van Dieren et al, 1996).
The effect of Auger electron cascades for IUdR can be deduced
by analyzing the shape of survival curves (Figures 4 and 6). The
absence of a shoulder indicates a defect in repair of DNA damages,
which are supposed to be more complex. On the contrary, survival
curves for iodine incorporated as contrast agent do not show any
loss of shoulder and seem to indicate a simple creation of an extra
number of both single strand breaks (SSB) and double-strand
breaks (DSB). For IUdR data, this leads to an extreme dependence
of the SER factor with the choice of the survival level S% used for
the calculation. The SER90% reaches a value of 9.5 around 90% of
cell survival rate, which could be worth considering for a
fractionated irradiation with low dose per fraction. On the
contrary, the ratios remain similar for iodinated contrast agent,
whatever the survival level chosen. The survival curves exhibit then
low-LET shapes, indicating that in both approaches, completely
different biophysical and molecular damages are generated inside
the DNA.
Some reserve has been expressed in the literature concerning the
potential clinical use of externally synchrotron-activated stable
IUdR (Miller et al, 1987a, b; Humm, 1988a; Humm and Charlton
1988b). Our encouraging results could certainly boost the debate.
The two new elements in the discussion could be the relative
effects of both the iodinated compounds and the choice of the
optimal energy to increase the enhancement ratios.
Other clinical applications could be found by associating a
monochromatic photon source with a heavy intratumoral element.
The ideal radioisotope would be one able to optimise interactions
with the targeted heavy atom. Of course, this limits the number of
(emitter –receptor) couples to be considered, but opens the way to
new source concepts (Karnas et al, 2001b). Samarium sources,
which emit monochromatic 40 keV g photons, could be used, for
instance, in association with stable iodine (Fairchild et al, 1987;
Laster et al, 1992). Energy deposited by 125I seeds during prostate
brachytherapy treatment could be enhanced by silver compounds
(Young et al, 1999) or other contrast agents like iodine,
gadolinium or lutetium as well (Norman et al, 2002).
However, the synchrotron tool appears to be the most useful one
for optimizing such a concept of bimodal radiotherapy and
monochromatic synchrotron radiotherapy, which exhibits promis-
ing in vivo results (Adam et al, 2003). This concept is hence
proposed as a promising technique for optimally increasing the
differential effect between healthy and cancerous tissue irradiation.
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contre le Cancer. Stéphanie Corde was supported by a fellowship
Optimal energy for stable iodine photon activation
S Corde et al
549
British Journal of Cancer (2004) 91(3), 544 – 551& 2004 Cancer Research UK
M
o
le
c
u
la
r
a
n
d
C
e
ll
u
la
r
P
a
th
o
lo
g
y
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